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Abstract: Reduction in brain-derived neurotrophic factor (BDNF) expression in the brain as well
as mutations in BDNF gene and/or of its receptor are associated to obesity in both human and
animal models. However, the association between circulating levels of BDNF and obesity is still not
defined. To answer this question, we performed a meta-analysis carrying out a systematic search in
electronic databases. Ten studies (307 obese patients and 236 controls) were included in the analysis.
Our data show that obese patients have levels of BDNF similar to those of controls (SMD: 0.01,
95% CI: −0.28, 0.30, p = 0.94). The lack of difference was further confirmed both in studies in which
BDNF levels were assessed in serum (MD: −0.93 ng/mL, 95% CI: −3.34, 1.48, p = 0.45) and in plasma
(MD: 0.15 ng/mL, 95% CI: −0.09, 0.39, p = 0.23). Data evaluation has shown that some bias might
affect BDNF measurements (e.g., subject recruitment, procedures of sampling, handling, and storage),
leading to a difficult interpretation of the results. Standardization of the procedures is still needed to
reach strong, affordable, and reliable conclusions.
Keywords: BDNF; obesity; meta-analysis
1. Introduction
Among the independent risk factors in cardiovascular disease (CVD), obesity is one of the most
relevant and increasing global epidemic, leading to higher morbidity and mortality and a shortening
in life expectancy [1].
Obesity is a metabolic dysfunction recently associated also with a low-grade inflammatory
state [2,3]. However, these findings do not explain the full clinical picture of obesity, and new
mechanisms responsible for the development and progression of this pathological condition are
under investigation. In particular, factors involved in the balance of energy expenditure control
lipid and glucose levels and cardiovascular homeostasis, are now considered as a new family named
metabotropic factors [4]. Interestingly, nerve growth factor (NGF) and brain-derived neurotrophic
factor (BDNF) have been included in this family [5].
This neurotrophin is synthetized not only in neurons but also in immune cells, adipocytes,
endothelial cells, and monocytes, and its levels are detectable in different tissues including brain and
blood [6–8].
The multifaceted role of BDNF, from his neurothrophic activity to his involvement in inflammation,
metabolism [5] and cardiovascular diseases [9,10], led to coining the term ‘triactome’, that effectively
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explains the tight interactions between brain, immune system, and adipose tissue and their role in
promoting the development of cardiometabolic diseases [11].
Actually, it has been established that hypothalamic reduction of BDNF modulates energy homeostasis
affecting food intake and promoting an anorectic signal [12]. Indeed, BDNF haploinsufficiency [13,14]
or missense mutations in its receptor, TrkB [15,16], are associated with hyperfagia, weight gain,
and obesity both in human and in mouse models. In line with these observations, both exogenous
BDNF administration and BDNF gene transfer in a mouse model of obesity and type 2 diabetes
mellitus restore normal food intake, inducing weight loss and decreasing insulin resistance [17,18],
which supports the concept that BDNF deficit in the brain induces a metabotropic impairment leading
to obesity [19,20].
Interestingly, the positive correlation between brain and circulating BDNF suggests that BDNF levels
in blood reflect the levels occurring in the central nervous system (CNS) [21]. Thus, circulating BDNF
has been proposed as a potential biomarker for neuro-psychiatric disorders and neurodegenerative
diseases [22–27]. On the contrary, the relationship between circulating BDNF and cardiometabolic
disorders is still unclear.
In this context, a significant reduction of circulating BDNF levels in obese subjects versus controls
was found [28,29], suggesting a negative association between circulating BDNF and this pathology [11,19].
However, in the last few years this relationship was called into question. Indeed, different studies
have shown either that circulating BDNF levels are higher in obese subjects than in controls [9,30] or
that there are no differences between the two groups [31]. In order to disentangle these controversies
regarding the association between circulating levels of BDNF and obesity, we performed a systematic
review and meta-analysis of the literature.
2. Results
2.1. Literature Search Process
After excluding duplicate results, the search retrieved 512 articles. Of these studies, 490 were
excluded because they were off the topic after scanning the title and/or the abstract and because
they were reviews/comments/case reports or they lacked data of interest. A total of 12 studies were
excluded after full-length paper evaluation. Thus, 10 studies on 307 obese patients and 236 controls
were included in the final analysis (Figure 1). In detail, we include three studies with children (94 cases
and 71 controls), and seven with the elderly (213 cases and 165 controls).
2.2. Study Characteristics
Table 1 and Table S1 describes the major characteristics of included studies. A total of five studies
were case-control, four had a prospective design, and one was cross-sectional.
The number of patients varied from 7 to 73, the mean age from 7.9 to >65 years, and the
prevalence of male gender from 0% to 100%. Mean body mass index (BMI) varied from 22.5 Kg/m2 to
34.00 Kg/m2, mean waist circumference from 72.00 cm to 98.10 cm. Mean total cholesterol level varied
from 156.40 mg/dL to 233.33 mg/dL, HDL cholesterol varied from 36.91 mg/dL to 56.86 mg/dL,
LDL cholesterol varied from 89.23 mg/dL to 155.27 mg/dL and triglycerides varied from 98.17 mg/dL
to 207.00 mg/dL. Mean glycaemia varied from 83.54 mg/dL to 102.53 mg/dL.
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In the 10 studies, we found that 307 obese patients have similar BDNF levels compared to
236 controls (SMD: 0.01, 95% CI: −0.28, 0.30, p-over = 0.94, I2 = 60%, p-heter = 0.003) (Figure 2).
As shown in Table 2, the lack of difference was consistently confirmed both in studies in which
BDNF levels were assessed in serum (MD: −0.93 ng/mL, 95% CI: −3.34, 1.48, p-over = 0.45,
I2 = 74%, p-heter = 0.0001) and in studies using plasma samples (MD: 0.15 ng/mL, 95% CI: −0.09, 0.39,
p-over = 0.23, I2 = 58%, p-heter = 0.07).
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Table 1. Demographic and clinical data of obese patients and healthy controls of the included studies.
Author, Country Study Design Type ofPathology
BDNF
Measurement
Cases
(n)
Controls
(n)
BDNF
(Ng/ML)
Cases
Mean
BDNF
(ng/mL)
Controls
Mean
BDNF
(ng/mL)
Weighted
Average
Age
(Years)
Cases
Age
(Years)
Controls
Age
(Years)
Mean
Males
(%)
BMI
(kg/m2)
Cases
BMI
(kg/m2)
Controls
BMI
(kg/m2)
Mean
WC
(cm)
Cases
WC
(cm)
Controls
WC
(cm)
Mean
Lee I-Te 2016,
Taiwan [32] Prospective
Obesity
and MetS Serum (ELISA) 36 25 40.40 43.00 41.47 44 39 41.95 100.0 33.5 22.5 29.0 109.1 81.9 98
Slusher AL 2015,
United States [30]
Case-control/
Prospective Obesity
Plasma
(ELISA) 11 11 1.72 0.98 1.35 22.91 23.27 23.09 40.9 35.72 21.89 28.8 99.32 71.36 85.3
Hinderberger P 2016,
Germany [31] Case-control Obesity Serum (ELISA) 24 14 28.10 27.10 27.73 36.9 36.1 36.61 26.3 40.7 22.5 34.0 ND ND ND
Gajewska E 2014,
Poland [33] Case-control
Obesity Serum (ELISA)
15 11 23.89 23.83 23.86 ≤65 ≤65 ≤65 0 >40 ND ND ND ND ND
39 25 24.11 23.22 23.76 >66 >66 >66 0 >40 ND ND ND ND ND
12 7 23.72 22.95 23.44 ≤65 ≤65 ≤65 100 >40 ND ND ND ND ND
14 21 24.74 23.94 23.99 >66 >66 >66 100 >40 ND ND ND ND ND
Han JC 2010, United
States [34] Cross-sectional Obesity Serum (ELISA) 13 13 17.60 14.20 15.90 12.3 12.4 12.35 92 33.1 17.2 25.2 ND ND ND
Corripio R 2012,
Spain [35] Prospective Obesity
Plasma
(ELISA) 73 47 57.70 78.50 65.85 8.03 7.74 7.92 55.8 26.5 16.2 22.5 81.3 57.5 72.0
Lee I-Te 2012,
Taiwan [36] Case-control
Obesity
and MetS Serum (ELISA) 34 24 40.90 43.20 41.85 41 39 40.17 100 33.9 22.5 29.2 109.3 82.2 98.1
Lee SS 2014, Korea [37] Prospective Obesity Serum (ELISA) 8 11 8.00 21.20 15.64 16.3 16.4 16.36 65 27.47 22.35 24.5 ND ND ND
Levinger I 2007,
Australia [38] Prospective
Obesity
and MetS
Plasma
(ELISA) 14 10 1.03 0.70 0.89 51.9 48.9 50.65 54 30.3 23.8 27.6 99.4 81 91.7
Chun-Jung Huang 2014,
United States [39] Case-control Obesity
Plasma
(ELISA) 14 17 0.28 0.20 0.24 22.64 22.94 22.80 35 38.18 21.21 28.9 111.46 68.74 88.0
WC: waist circumference; BMI: body mass index; ND: not declared.
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value of NOS quality assessment was 3. Thus, four studies were considered “low quality” (NOS < 3) 
(Table 3). Of interest, after excluding these studies, all results were entirely confirmed (Figure 3). 
  
Figure 2. Brain derived neurotrophic factor (BDNF) levels in obese patients and controls.
Table 2. Subgroup analysis: stratification of the analysis according to different BDNF matrices used for
BDNF measurements.
Number of Studies Number of Patients Effect Size Test for SubgroupDifferences
Serum 6 195 cases 151 controls MD: −0.93; 95% CI: −3.34, 1.48,p = 0.45, I2: 74%, p = 0.0001
Chi2: 0.88, p = 0.35
Plasma 4 112 cases 85 controls MD: 0.15; 95% CI: −0.09, 0.39,p = 0.23, I2: 58%, p = 0.07
MD: Mean Di fere I: Confidence Interval; Chi2: chi-squared.
No heterogeneity reduction was observed even after excluding one study at time. The median
value of NOS quality assessment was 3. Thus, four studies were considered “low quality” (NOS < 3)
(Table 3). Of interest, after excluding these studies, all results were entirely confirmed (Figure 3).
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2.3. Meta-Regression Analyses 
Meta-regression models showed that cardiovascular (CV) risk factors (hypertension, diabetes, 
hyperlipidemia, and smoking habit) (Figure S1) and demographic variables (male gender and age) 
(Figure S2) did not influence the association between BDNF levels and obesity. Because it is 
recognized that publication bias affects the results of meta-analyses, we attempted to assess this 
potential bias using funnel plot analysis. Funnel plots of effect size versus standard error for studies 
evaluating levels of BDNF in obese patients and controls were rather asymmetrical, and the Egger 
test confirmed the absence of a significant publication bias (Egger’s p = 0.49, Figure 4). 
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Table 3. Quality assessment (Newcastle–Ottawa scale) of 10 studies.
Definition
of Cases
Representativeness
of Cases
Selection
of Controls
Definition
of Controls
Comparability
of Cases
and Controls
Same Method
of Ascertainment Quality
Lee I-Te, 2016 [31]
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2.3. Meta-Regression Analyses 
Meta-regression models showed that cardiovascular (CV) risk factors (hypertension, diabetes, 
hyperlipidemia, and smoking habit) (Figure S1) and demographic variables (male gender and age) 
(Figure S2) did not influence the association between BDNF levels and obesity. Because it is 
recognized that publication bias affects the results of meta-analyses, we attempted to assess this 
potential bias using funnel plot analysis. Funnel plots of effect size versus standard error for studies 
evaluating levels of BDNF in obese patients and controls were rather asymmetrical, and the Egger 
test confirmed the absence of a significant publication bias (Egger’s p = 0.49, Figure 4). 
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2.3. Meta-Regression Analyses 
Met -reg ession m dels show d that cardiovascular (CV) risk factors (hypertension, diabetes, 
hyperlipidemia, and smoking h bit) (F gure S1) and demographic variables (male gender and age) 
(Figure S2) did not influence the asso iation between BDNF levels and obesity. Because it is 
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Meta-regression dels showed that cardiovascular (CV) risk factors (hypertension, diabetes, 
yperlipid mia, and smoking h bit) (Figure S1) and demographic variables (male gender and age) 
(Figure S2) did not influenc the association between BDNF levels and obesity. Because it is 
recognized that ublication bias affects the results of meta-analyses, we attempted to assess this 
potential bias using funnel plot analysis. Funnel plots of effect size versus standard error for studies 
evaluating lev ls of BDNF in obese patients and controls were rather asymmetrical, and the Egger 
test confirmed the absence of a significant publication bias (Egger’s p = 0.49, Figure 4). 
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3. Discussion
To the best of our knowledge, this is the first meta-analysis investigating the associ ti n between
circulating levels of BDNF and obesity. The current meta-analysi is not able to find any association
between BDNF levels, both in plasma and in serum, and obesity. These findings were further confirmed
by the sensitivity analysis, suggesting that at the current state of the art there is no evidence regarding
this association.
The current opinion that obesity is associated with lower levels of circulating BDNF [11,19],
and that restoring its physiological levels by administration of exogenous BDNF may prevent the
detrimental effect of the metabolic syndrome [11] should be considered carefully.
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Indeed, whereas the correlation between obesity and hypothalamic BDNF reduction in both
human and animal models [40–43] is well established, the association of this pathology with circulating
BDNF derives predominantly only from the assumption that circulating BDNF mirrors the one in the
brain. It has been hypothesized that BDNF from the brain moves into circulation after crossing the
blood–brain barrier [21]. However, the hypothesis that circulating BNDF derives only from brain is
now under debate, and although, vascular endothelium [8] has been proposed as a source of circulating
BDNF, its origins are still poorly understood [44,45].
BDNF is detectable in plasma even if its levels are 100 to 200-fold lower in plasma than those of
serum. Plasma BDNF levels change within a day and can be influenced by environmental factors and
correlate positively with platelets activation state [46–48] and might well reflect the physio-pathological
condition of the body [49]. However, plasma BDNF is quite unstable [50] and sensitive to preparation
procedure [51–53].
On the other hand, serum BDNF mostly reflects the total amount of this neurotrophin released
from the alpha granules of platelets after blood clotting [47]. Serum BDNF is more stable, also after
long term storage [51] but its amount in serum is modified by temperature and time of clotting [46].
According to other studies [30,31], we did not find a significant difference among the analyzed groups.
However, the results here obtained might be influenced by potential limitations that are herein
critically discussed.
First, criteria for patient or control recruitment frequently do not take into account parameters
and/or factors that affect BDNF measurements [54–56]. Among these, we can find metabolic
dysfunctions as well as smoke history, sex, age, and ethnicity. It is important to consider that history
of previous smoking has a recognized impact on circulating BDNF levels [48]. Therefore, smokers
should be excluded from studies assessing circulating levels of the protein. Interestingly, only in one
study [30] was it clearly declared that smoke history represented one of the exclusion criteria used.
In addition, since it has been reported that plasma BDNF levels differ between females and
males both in plasma and serum [44,49], the high variability in the percentage of male in the studies
(ranging from 0 to 100%) have an impact on the results.
Three studies were carried out in children and/or adolescents. Since it has been reported that
hormonal status influences circulating BDNF [57], evaluation of BDNF concentrations might be
interpreted with age-specific standard. In line with this, we cannot exclude an impact of data deriving
from prepubertal patients and controls on our results.
In this meta-analysis we included in the analysis studies with both people of Western European
descent and Asian subjects, even if it is known that these two ethnic groups have different circulating
levels of BDNF and pro-BDNF [58]. Similarly, differences in allelic prevalence of BDNF polymorphisms
that might affect protein circulating levels and are associated with obesity [59] were found among
ethnic groups [60].
Based on these considerations, we performed a meta-regression analyses to assess if differences
in the effect size among included studies may be affected by demographic variables (e.g., age and
gender) (Figure S2), coexistence of traditional CV risk factors (e.g., hypertension, smoking habit,
hyperlipidemia, and diabetes) (Figure S1). However, these factors and variables did not influence the
association between BDNF levels and obesity previously observed.
In addition, procedures of sampling, handling, and storage are not always reported (Table 4),
making difficult to critically analyze the data provided.
In particular, the high variability of plasma levels (ranging from 0.2017 ± 0.04198 to
57.7 ± 40.7 ng/mL) and serum (ranging from 8.0 ± 6.6 to 43.2 ± 6.1 ng/mL) of BDNF represents
a major bias for our analysis. Of note, the value of plasma BDNF reported by Corripio et al.
(57.70 ± 40.70 ng/mL for cases and 78.50 ± 85.00 ng/mL for obese) is about 50-fold higher than
that reported by the other studies, and surprisingly it is similar to the levels reported in serum [44,49].
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Table 4. Characteristics regarding procedures of sampling, patients condition, handling, storage, and measurements of BDNF.
Author Sample Information Reported aboutBlood Collection Patients Condition
Information Reported
about Procedure to
Obtain Plasma/Serum
Conservation Assay Kit
Lee I-Te 2016 [31] Serum ND ND ND ND ELISA Quantikine; R&D Systems, Inc.,Minneapolis, MN
Slusher AL 2015 [29] Plasma Blood collected in EDTA tubes(BD vacutainer) ND
Immediately centriguged
at 1000× g for 20 min at
room temperature
−80 ◦C until measurements
(no reported storage time) Promega, Madison, WI
Hinderberger P
2016 [32] Serum
Blood collected in two timeframes:
8–10 a.m. and 2–4 p.m. ND 2 h of clotting ND
ELISA Quantikine; R&D Systems, Inc.,
Minneapolis, MN
Gajewska E 2014 [33] Serum ND ND ND ND ELISA Quantikine; R&D Systems, Inc.,Minneapolis, MN
Han JC 2010 [34] Serum Serum obtained using serumseparator tubes ND 30 min of clotting
−70 ◦C until measurements
(no reported storage time)
ELISA Quantikine; R&D Systems, Inc.,
Minneapolis, MN
Corripio R 2012 [35] Plasma ND Samples obtainedafter 12 h of fasting ND
−80 ◦C until measurements
(no reported storage time)
Human BDNF ELISA Kit, RayBiotech,
Inc, Norcross, GA
Lee I-TE 2012 [36] Serum ND ND ND ND ELISA Quantikine; R&D Systems, Inc.,Minneapolis, MN
Lee SS 2014 [37] Serum ND Samples obtainedafter 12 h of fasting
Centrifugation at
3000 rpm for 10 min
−80 ◦C until measurements
(no reported storage time)
ELISA Quantikine; R&D Systems, Inc.,
Minneapolis, MN
Levinger I 2007,
Australia [38] Plasma ND
Samples obtained
after 3 h of fasting ND
−20 ◦C until measurements
(no reported storage time)
ELISA Quantikine; R&D Systems, Inc.,
Minneapolis, MN
Chun-Jung Huang
2013 [39] Plasma Blood collected in EDTA tubes ND
Centriguged at 2000× g
for 15 min at 4 ◦C
−80 ◦C until measurements
(no reported storage time) Abcam, Cambridge, MA
ND: Not Declared.
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Concerning methodological aspects, it is well-known that different anticoagulants, temperatures,
and delays in sample centrifugation, as well as conditions and time of sample storage influence the
measurements of BDNF [46,51,53,61]. Similarly, the ELISA kits used to measure BDNF have different
performance in terms of detection range, sensitivity, and inter-assay variations [62]. In the studies
included in our meta-analysis, all the authors correctly specified the producers; however, it cannot be
excluded that inter-kit variability plays an important role in BDNF measurements.
Finally, information about the effects of fasting or fed conditions were often not available even if
it has been shown that diet affects circulating BDNF [63].
4. Materials and Methods
In order to provide a comprehensive search and analysis of data we followed a standardized
research protocol already performed by our group [64]. Briefly, prospectively developed, detailing
the specific objectives, the criteria for study selection, the approach to assess study quality, outcomes,
and statistical methods.
4.1. Search Strategy
To identify all available studies, a detailed search pertaining to BDNF levels and obesity was
conducted according to PRISMA (preferred reporting items for systematic reviews and meta-analyses)
guidelines [65]. A systematic search was performed in the electronic databases (PubMed, Web of
Science, Scopus, EMBASE), using the following search terms in all possible combinations: brain derived
neurotrophic factor, BDNF, obesity, overweight, body mass index (BMI). The last search was
performed on 11 June 2018. The search strategy was developed without any language or publication
year restriction.
In addition, the reference lists of all retrieved articles were manually reviewed. In case of missing
data, study authors were contacted by e-mail to try to retrieve original data. Two independent authors
(L.S. and P.A.) analyzed each article and performed the data extraction independently. In case of
disagreement, a third investigator was consulted (A.D.M). Discrepancies were resolved by consensus.
Selection results showed a high inter-reader agreement (κ = 0.96) and have been reported according to
PRISMA flowchart (Figure 1).
4.2. Data Extraction and Quality Assessment
According to the pre-specified protocol, all studies evaluating BDNF levels in obesity patients
were included. Case-reports, reviews and animal studies were excluded.
To be included in the analysis, a study had to provide levels of BDNF in obese patients (BMI > 30)
and controls. We also included the studies of Lee SS et al. and Corripio et al [35,37] that involved obese
children with BMI < 30 since the authors stated that the patients were obese according to the guidelines.
To allow for a pooled analysis of data, studies dosing BDNF levels on samples different from
plasma or serum (i.e., histological samples), lacking of a control group, including a study population
with a clinical condition other than obesity were excluded.
In each study, data regarding sample size, major clinical and demographic variables of patients,
and controls and type of BDNF measurement (different commercially available kits for the dosage of
BDNF) were extracted.
4.3. Statistical Analysis and Risk of Bias Assessment
Statistical analysis was carried out using the Review Manager software (Version 5.2, The Cochrane
Collaboration, Copenhagen, Denmark). Because of the heterogeneity in the methods used for
measuring BDNF in included studies, differences among cases and controls were expressed as
standard mean difference (SMD) with pertinent 95% confidence intervals (95% CI). According to
widely accepted guidelines, SMD is considered small if ranging from 0.2 to 0.5, medium if 0.5–0.8
and large if >0.8 [66]. When separately assessing, studies in which BDNF levels were evaluated
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in plasma and serum, differences among cases and controls were expressed as mean difference
(MD) with 95% CI. The overall effect was tested using Z scores and significance was set at p < 0.05.
Statistical heterogeneity between studies was assessed with chi square Cochran’s Q test and with
I2 statistic, which measures the inconsistency across study results and describes the proportion of
total variation in study estimates, that is due to heterogeneity rather than sampling error. In detail,
I2 values of 0% indicates no heterogeneity, 25% low, 25–50% moderate, and 50% high heterogeneity [67].
Publication bias was assessed by the Egger’s test and represented graphically by funnel plots of the
standard difference in means versus the standard error (Figure 4). Visual inspection of funnel plot
asymmetry was performed to address for possible small-study effect, and Egger’s test was used
to assess publication bias, over and above any subjective evaluation. A p < 0.10 was considered
statistically significant [68]. In case of a significant publication bias, the Duval and Tweedie’s trim
and fill method was used to allow for the estimation of an adjusted effect size [69]. In order to be as
conservative as possible, the random-effect method was used for all analyses to take into account the
variability among included studies.
4.4. Meta Regression Analyses
We hypothesized that differences in the effect size among included studies may be affected
by demographic variables (mean age, male gender) and coexistence of traditional CV risk factors
(hypertension, smoking habit, hyperlipidemia, diabetes). To assess the possible effect of such variables
in explaining different results observed across studies, we planned to perform meta-regression analyses
after implementing a regression model with BDNF levels as a dependent variable(y)—expressed as
standardized mean difference—and the above-mentioned co-variates as independent variables (x).
This analysis was performed with comprehensive meta-analysis (Version 2, Biostat, Englewood,
NJ, USA, (2005)).
4.5. Sensitivity Analysis
In the frame of a sensitivity analysis, we repeated analyses by including only the studies judged
as “high quality” according to Newcastle–Ottawa scale (NOS) [70]. Briefly, we judged each study by
its quality by awarding a star for each item that was present. Studies reaching a value of NOS ≥ to the
median value found among all the studies were included for sensitivity analysis.
5. Conclusions
In conclusion, our meta-analysis shows that obesity is apparently not associated with lower levels
of circulating BDNF. However, considerations regarding the limitations deriving from criteria of subject
selection and methodological aspects are often underestimated. This leads to a difficult interpretation
of the results and makes it more difficult to reach strong, affordable, and reliable conclusions when
comparing data from studies present in the literature.
Supplementary Materials: Supplementary materials can be found at http://www.mdpi.com/1422-0067/19/8/
2281/s1. Figure S1: Scatterplot of the relationship between hypertension, diabetes, hyperlipidemia and smoking
habit and standard mean difference. Figure S2: Scatterplot of the relationship between male gender and age
and mean difference. Table S1: Demographic and clinical data of obese patients and healthy controls of the
included studies.
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